Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Non-Hodgkin Lymphoma

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04012892

Enrollment

Registered

2019-07-09

Start date

2019-05-01

Completion date

2021-06-01

Last updated

2019-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma

Brief summary

This study is a single-arm, open label, phase I clinical trial to evaluate the safety and feasibility of CD19CAR-T in treatment of relapsed / refractory non-hodgkin lymphoma

Interventions

COMBINATION_PRODUCTCD19 CART

CD19 CART

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. Diagnosis with Relapsed or refractory Non Hodgkin Lymphoma with CD19 positive 2. Age 18 to 65 years old, both male and female; 3. Is expected to survive more than 12 weeks; 4. Physical condition is good: 0-1 score ECOG score; 5. No obvious abnormal heart, liver, kidney, no large wounds that haven't healed on the body; 6. Into groups to participate in voluntarily, good adherence, can cooperate test observation, childbearing age women must be 7 days before starting treatment expert pregnancy test and the results were negative, and signed a written informed consent form.

Exclusion criteria

1. Organ failure, such as heart: Class III and IV; liver: to Child grading of liver function grade C; kidney: kidney failure and uremia stage; lung: symptoms of severe respiratory failure; brain: disorder of consciousness; 2. Existing serious acute infection, uncontrollable, or have fester sex and chronic infection, wound in delay no more; 3. Pregnancy and lactation women; 4. Patients who have participated in other clinical trials or other clinical trials in the past 30 days; 5. The Investigator believe the patients should not participate in this experiment.

Design outcomes

Primary

Measure	Time frame	Description
recovery rate of patients being treated with CD19CAR-T	6 months	the recovery rate of patients consists of complete recovery rate and partial recovery rate of patients being treated with CD19 CAR-T

Countries

China

Contacts

Primary ContactLixing Wang, MD

wanglixin1991@sohu.com86-0755-21839178

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026